INT17685

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1982
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 23
Total Number 23
Disease Relevance 15.65
Pain Relevance 3.56

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Cog1) Golgi apparatus (Cog1)
Anatomy Link Frequency
plasma 1
blood 1
body 1
Cog1 (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 8 99.98 Very High Very High Very High
rheumatoid arthritis 46 99.88 Very High Very High Very High
Versed 10 99.32 Very High Very High Very High
Inflammation 82 97.32 Very High Very High Very High
tolerance 1 97.24 Very High Very High Very High
Percutaneous transluminal coronary angioplasty 10 97.08 Very High Very High Very High
Angina 17 96.04 Very High Very High Very High
Clonidine 5 86.80 High High
transdermal 8 86.40 High High
Bile 19 85.68 High High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 106 100.00 Very High Very High Very High
Myocardial Infarction 91 100.00 Very High Very High Very High
Death 29 100.00 Very High Very High Very High
Stroke 9 100.00 Very High Very High Very High
Rheumatoid Arthritis 46 99.88 Very High Very High Very High
Cardiovascular Disease 94 99.54 Very High Very High Very High
Dyslipidemia /

Combined Dyslipidemia

24 99.52 Very High Very High Very High
Left Ventricular Hypertrophy 1 98.76 Very High Very High Very High
Cytomegalovirus Infection 7 98.20 Very High Very High Very High
Coronary Artery Disease 132 97.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, such treatment reduces oxygen consumption, levels of total cholesterol, triglycerides, low density lipoprotein cholesterol.
Negative_regulation (reduces) of low density lipoprotein associated with disorder of lipid metabolism
1) Confidence 0.42 Published 2002 Journal Klin Med (Mosk) Section Abstract Doc Link 12360622 Disease Relevance 0.27 Pain Relevance 0.24
In the midazolam group, we observed a significant decrease in low-density lipoprotein, cholesterol at the end of cardiopulmonary bypass, end of surgery, and 4 and 24 h postoperatively and significant increase in osmolality at the end of cardiovascular bypass.
Negative_regulation (decrease) of low-density lipoprotein associated with versed
2) Confidence 0.42 Published 2007 Journal Yakugaku Zasshi Section Abstract Doc Link 17202798 Disease Relevance 0 Pain Relevance 0.32
In vitro data suggest that vitamin E protects against oxidation of low-density lipoprotein and decreases the deposition of atherogenic oxidized low-density lipoprotein in arterial walls.
Negative_regulation (decreases) of low-density lipoprotein
3) Confidence 0.37 Published 1999 Journal Arch. Intern. Med. Section Abstract Doc Link 10386507 Disease Relevance 0.69 Pain Relevance 0.08
There was a significant reduction in the levels of total cholesterol and low density lipoprotein cholesterol.
Negative_regulation (reduction) of low density lipoprotein associated with disorder of lipid metabolism
4) Confidence 0.31 Published 1991 Journal Kardiologiia Section Abstract Doc Link 2046243 Disease Relevance 0.35 Pain Relevance 0.17
Low-density lipoprotein cholesterol decreased significantly (3.2 +/- 1.0 vs 2.7 +/- 0.7 mmol/L, p < 0.001).
Negative_regulation (decreased) of Low-density lipoprotein
5) Confidence 0.25 Published 2000 Journal Am. J. Cardiol. Section Abstract Doc Link 11078304 Disease Relevance 1.22 Pain Relevance 0.22
The reduced low density lipoprotein phospholipids and the increased high density lipoprotein apo-A correlated with the plasma concentration of propranolol and metoprolol, respectively.
Negative_regulation (reduced) of low density lipoprotein in plasma
6) Confidence 0.22 Published 1982 Journal Int J Clin Pharmacol Ther Toxicol Section Abstract Doc Link 6125482 Disease Relevance 0.43 Pain Relevance 0.12
Further, estrogen has strong antioxidant properties, including inhibition of low-density lipoprotein oxidation, decreased lipoprotein levels, and reduction in superoxide production [29,33,34].
Negative_regulation (inhibition) of low-density lipoprotein
7) Confidence 0.20 Published 2006 Journal J Inflamm (Lond) Section Body Doc Link PMC1764413 Disease Relevance 0.66 Pain Relevance 0.10
Tamoxifen induces a decrease in total cholesterol and low-density lipoprotein levels and an increase in triglyceride concentration, but no change has been reported for high-density lipoprotein serum concentration.
Negative_regulation (decrease) of low-density lipoprotein associated with disorder of lipid metabolism
8) Confidence 0.18 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2802286 Disease Relevance 1.39 Pain Relevance 0.19
Soybean-protein diet, legumes, nuts and soluble fibre significantly decrease total cholesterol, low-density lipoprotein cholesterol and triglycerides.
Negative_regulation (decrease) of low-density lipoprotein associated with disorder of lipid metabolism
9) Confidence 0.09 Published 1999 Journal QJM Section Abstract Doc Link 10627874 Disease Relevance 0.45 Pain Relevance 0.06
This in vivo approach resulted in reduction of the elevated intermediate density lipoprotein (IDL)/LDL ratio to normal levels, four days after vector delivery [129].
Negative_regulation (reduction) of intermediate density lipoprotein associated with disorder of lipid metabolism
10) Confidence 0.06 Published 2010 Journal Int Arch Med Section Body Doc Link PMC3016243 Disease Relevance 0.62 Pain Relevance 0
In addition to reducing total (TC) and low density lipoprotein (LDL-C) cholesterol, fluvastatin has antiatherogenic, antithrombotic and antioxidant effects, can improve vascular function, and may have immunomodulatory effects.
Negative_regulation (reducing) of low density lipoprotein
11) Confidence 0.06 Published 1999 Journal Drugs Section Abstract Doc Link 10235694 Disease Relevance 0.53 Pain Relevance 0.04
Mean serum high density lipoprotein-cholesterol levels are increased and low density lipoprotein-cholesterol levels are decreased during treatment with oral estradiol plus sequential dydrogesterone.
Negative_regulation (decreased) of low density lipoprotein-cholesterol
12) Confidence 0.05 Published 1997 Journal Drugs Aging Section Abstract Doc Link 9342560 Disease Relevance 0.67 Pain Relevance 0.12
Another study showed a significant increase in the proportion of patients receiving screening and a reduction in total cholesterol and low-density lipoprotein cholesterol levels when pharmacists were responsible for monitoring and titrating medications, and monitoring laboratory testing [61].
Negative_regulation (reduction) of low-density lipoprotein associated with disorder of lipid metabolism
13) Confidence 0.03 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2323373 Disease Relevance 0.10 Pain Relevance 0.08
However, the 24% relative reduction of low-density lipoprotein cholesterol is similar to that observed in long-term lipid-lowering trials that demonstrated significant reductions in mortality [40].
Negative_regulation (reduction) of low-density lipoprotein
14) Confidence 0.03 Published 2001 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC59530 Disease Relevance 0.64 Pain Relevance 0.03
No significant decrease in pulse or change from baseline in lipid profiles (high-density lipoprotein, low-density lipoprotein, apolipoprotein A-I, apolipoprotein B) was observed with combination therapy.
Neg (No) Negative_regulation (decrease) of low-density lipoprotein associated with disorder of lipid metabolism
15) Confidence 0.03 Published 1991 Journal Clin Ther Section Abstract Doc Link 1933999 Disease Relevance 0.42 Pain Relevance 0.60
The intervention was successful in reducing low-density lipoprotein levels over the short-term and the effects persisted 18 months after discontinuation of the intervention; the proportion of patients achieving the low-density lipoprotein cholesterol goal also increased significantly [62].
Negative_regulation (reducing) of low-density lipoprotein
16) Confidence 0.03 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2323373 Disease Relevance 0.21 Pain Relevance 0.06
Three months after intensive periodontal treatment in patients with a proven history of cardiovascular disease there was significant reduction in levels of CRP and oxidised low density lipoprotein [14]; associated host responses contribute to the manifestations of clinical parameters of periodontal disease [15].
Negative_regulation (reduction) of low density lipoprotein associated with cardiovascular disease and periodontal disease
17) Confidence 0.02 Published 2008 Journal The Open Dentistry Journal Section Body Doc Link PMC2581528 Disease Relevance 1.83 Pain Relevance 0.20
In fact, alpha 1 antagonists reduce total cholesterol and low-density-lipoprotein plus very-low-density-lipoprotein cholesterol and thus may contribute to the overall management of cardiovascular risk by blood pressure reduction and improvement of the serum lipid profile.
Negative_regulation (reduce) of low-density-lipoprotein in blood associated with antagonist and disorder of lipid metabolism
18) Confidence 0.02 Published 1989 Journal Am. J. Hypertens. Section Abstract Doc Link 2572243 Disease Relevance 0.96 Pain Relevance 0.21
Low-density lipoprotein and triglycerides also decreased significantly (p < 0.01).
Negative_regulation (decreased) of Low-density lipoprotein
19) Confidence 0.02 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994008 Disease Relevance 0.90 Pain Relevance 0.03
Studies on carbohydrate metabolism, lipid and hemostatic parameters showed that high density lipoprotein increases, and low density lipoprotein decreases, thus suggesting cardioprotective benefit.
Negative_regulation (decreases) of low density lipoprotein
20) Confidence 0.01 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778416 Disease Relevance 0.54 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox